Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Matthew J FrankNasheed M HossainAli BukhariErin A DeanJay Y SpiegelGursharan K ClaireIlan KirschAllison P JacobChelsea D MullinsLik Wee LeeKatherine A KongJuliana K CraigCrystal L MackallAaron P RapoportMichael D JainSaurabh DahiyaFrederick L LockeDavid Bernard MiklosPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Noninvasive ctDNA assessments can risk stratify and predict outcomes of patients undergoing axi-cel for the treatment of large B-cell lymphoma. These results provide a rationale for designing ctDNA-based risk-adaptive chimeric antigen receptor T-cell clinical trials.
Keyphrases
- circulating tumor
- clinical trial
- cell free
- circulating tumor cells
- patients undergoing
- diffuse large b cell lymphoma
- phase ii
- phase iii
- low dose
- randomized controlled trial
- metabolic syndrome
- skeletal muscle
- weight loss
- insulin resistance
- free survival
- loop mediated isothermal amplification
- quantum dots
- sensitive detection
- combination therapy